Our Company was originally incorporated as "Anthem Biosciences Private Limited" under the provisions of the Companies Act, 1956, pursuant to a certificate of incorporation dated June 13, 2006, issued by RoC. Subsequently, our Company was converted from a private company to a public company, pursuant to a board resolution dated October 18, 2024 and a resolution passed in the extraordinary general meeting of our Shareholders held on October 18, 2024 following which the name of our Company was changed to "Anthem Biosciences Limited" and a certificate of incorporation consequent upon conversion to public limited company was issued by the RoC on December 10, 2024.Major Events and Milestones:2006- Incorporation of our Company.2007- Commenced operations of our Company at Unit I and set up a custom synthesis plant with a capacity of 6 KL.2008- Commencement of the discovery biology services with a fermentation capacity of 2 KL.2010- Expanded the custom synthesis plant set up at Unit I increasing its capacity from 6 KL to 24 KL.2013- Received the first USFDA audit approval for Unit I.2016- Set up a high potent lab at Unit I - Bommasandra Facility.2017- Our Company, pursuant to an order dated November 30, 2017, amalgamated with Anthem Cellutions (India) Private Limited by way of an acquisition of 100% of its share capital.- Set up a solid phase peptide synthesis GMP lab with a capacity of 6 KL at Unit 1.- Commenced operations of our Company at Unit II and set up an automated GMP compliant custom synthesis plant with a capacity of 128 KL and a fermentation plant with a capacity of 80 KL.- Received the second USFDA audit approval for Unit I.2018- Anthem Cellutions (India) Private Limited amalgamated into our Company.2019- Received the third USFDA approval for Unit I.- Set up a flow chemistry lab at Unit I.2020- Commenced operations in biological facility 2 earmarked for a specific client.2022- Expanded the custom synthesis plant set up at Unit II increasing its capacity to 246 KL.2023- Received the first USFDA audit approval and first therapeutic goods administration audit for Unit II.- Addition of Oligonucleotide lab in Unit I.- Set a cGMP scale continuous flow manufacturing facility for Unit II.2024- Received the: second USFDA audit approval for Unit II; first ANVISA audit approval for Unit I(1); and first ANVISA audit approval for Unit II(1).- Commenced operations of Neoanthem Lifesciences Private Limited, at Unit III designed as a chemistry lab and customer synthesis pilot plant for development, technology transfer and scale-up projects.- Fermentation capacity expanded to 140 KL at Unit II.- Conversion of our Company into a public limited company, under the name "Anthem Biosciences Limited".2025- Received the fourth USFDA approval for Unit I.